期刊
CELL
卷 159, 期 4, 页码 721-726出版社
CELL PRESS
DOI: 10.1016/j.cell.2014.10.016
关键词
-
资金
- European Research Council (ERC)
- Stichting Alzheimer Onderzoek (SAO)
- Fonds voor Wetenschappelijk Onderzoek (FWO)
- KU Leuven and Leuven University fund
- Vlaams Instituut voor Biotechnologie (VIB)
- KU Leuven/Flemish Government
- IUAP P7/16 NEUROBRAINNET network
- Vlaams initiatief voor dementia (VIND)
- Janssen Pharmaceutica
gamma-Secretase proteases have been associated with pathology in Alzheimer disease (AD), but we are just beginning to understand their basic mechanisms and physiological roles. A negative drug trial with a broad spectrum gamma-secretase inhibitor in AD patients has severely dampened enthusiasm for the potential of pursuing gamma-secretase research therapeutically. This pessimism is unwarranted: analysis of available information presented here demonstrates significant confounds for interpreting the outcome of the trial and argues that the major lessons pertain to broad knowledge gaps that are imperative to fill.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据